Key Takeaway: CorMedix Inc. will participate in upcoming investor conferences in September, including the Cantor Global Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference. The company is focused on developing therapeutic products for life-threatening diseases, with its lead product, DefenCath®, launched in both inpatient and outpatient settings. Additionally, CorMedix is initiating clinical studies in Total Parenteral Nutrition and pediatric populations.
Price reaction · baseline $14.14 (2025-08-27 close) · hit pre-market · 1 other CRMD headline(s) in the window, move may be shared
day 0 close · peak
+1.5%
Market Sentiment Analysis
POSITIVE FACTORS
CorMedix is actively engaging with investors at key conferences.
The company has successfully launched its product DefenCath®.
CorMedix is expanding its clinical studies into new patient populations.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
27.2%
average across 3 past catalysts
Lead asset
Solithromycin
Phase 3 · Community-acquired Bacterial Pneumonia
Full Press Release Details
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.
Cantor Global Healthcare Conference
Date:
September 5, 2025
Time:
8:35am Eastern
Format:
Fireside Chat
Webcast:
Link to webcast
Morgan Stanley 23rdAnnual Global Healthcare Conference
Date:
September 10, 2025
Time:
10:45am Eastern
Format:
Fireside Chat
Webcast:
Link to webcast
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®(taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath®in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix commenced clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath®as a catheter lock solution for use in other patient populations. For more information visit:www.cormedix.com.